Currently, two out of three known GnRH antagonists have defined doses: Elagolix, 150 mg recommended once daily for ≤24 months in patients who also suffer from dyspareunia; Elagolix, at a higher dose, 200 mg recommended twice daily for ≤6 months. Here, GNRH1 is linked to Dyspareunia.